The Clinical Significance of p21 Expressionin Gastric Adenocarcinoma.
- Author:
Seung Joo KIM
1
;
Gil Soo SON
Author Information
1. Department of Surgery, Korea University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
p21 immunoreactivity;
Gastric adencarcinoma
- MeSH:
Adenocarcinoma*;
Cell Differentiation;
Cyclin-Dependent Kinases;
Humans;
Immunohistochemistry;
Lymph Nodes;
Neoplasm Metastasis;
Prognosis
- From:Journal of the Korean Surgical Society
1998;55(1):65-69
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUNDS: The p21 protein inhibits cyclin-dependent kinases and mediates cell-cycle arrest and cell differentiation. METHODS: This study was performed in 61 patients with gastric adenocarcinoma to investigate the realtionship between p21 expression and clinicopathological findings, and the usefulness of p21 as a prognostic factor. Correlation was determined between p21 immunoreactivity by immunohistochemistry and clinicopathological features, including the clinical outcome. RESULTS: Immunoreactivity for p21 was detected in 31 (50.8%) patients. There were no significant correlations between the presence or absence of p21 immunoreactivity and age, sex, site, tumor invasion, tumor size, lymph node metastasis, distant metastasis, or stage except histologic subtype (P=0.002). Survival curves revealed that there was no significant difference of the prognosis between patients with p21 expression and those without p21 expression (P=0.836). CONCLUSIONS: Immunohistochemical analysis of p21 was not useful for evaluating the prognosis and biological status of patients with gastric adenocarcinoma.
